Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Eton Pharmaceuticals (ETON) Stock Price & Analysis

591 Followers

ETON Stock Chart & Stats

$50.95$0.14(0.28%)
At close: 4:00 PM EST
$40$50$60Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$50.50 - $52.68
52-Week Range
$14.27 - $66.37
Previous Close
$50.81
Volume
N/A
Average Volume (3M)
535.91K
Market Cap
$1.45B
Enterprise Value
$1.19B
Total Cash (Recent Filing)
$26.84M
Total Debt (Recent Filing)
$28.99M
Price to Earnings (P/E)
109.6
Beta
0.57
Next Earnings
Nov 05, 2026 (Est.)
EPS Estimate
0.31
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Margin Expansion

The sharp increase in revenue and adjusted EBITDA, together with raised full-year guidance, indicates meaningful operating leverage in Eton’s commercial model. If maintained, stronger margins and scale can support internal funding for acquisitions, development programs, and debt reduction over the next several quarters.

Rare Disease Portfolio Expansion

The LIBERVANT agreement broadens Eton’s rare disease portfolio and establishes a neurology platform alongside existing pediatric and specialty products. Exclusive rights, orphan designation, and long patent protection could support differentiated commercialization and create a durable future revenue stream if FDA approval is completed.

Specialty Commercial Infrastructure

Rapidly transitioning approximately 95% of existing HEMANGEOL patients demonstrates that Eton’s patient-support, distribution, and specialist commercial infrastructure can drive adoption in rare diseases. This capability is reusable across products and may lower commercialization friction for future launches and relaunches.

Bears Say

Profitability Track Record

The move to profitability is substantial, but the company has only recently established positive earnings after near-breakeven or loss-making annual results. A short profitability history makes it harder to confirm that current margins are durable across product cycles, launches, and development spending.

Cash And Investment Demands

The cash balance is modest relative to planned licensing, clinical, and research expenditures, even after strong recent cash generation. Funding several programs while accelerating credit-facility repayment could reduce financial flexibility and make execution more sensitive to launch timing or operating cash-flow variability.

Lower-Margin Product Economics

IMPAVIDO can expand Eton’s rare disease portfolio, but the large partner profit share means its contribution should carry lower margins than some internally commercialized products. A growing mix of such arrangements could limit consolidated margin expansion and reduce the cash retained from product sales.

Eton Pharmaceuticals News

ETON FAQ

What was Eton Pharmaceuticals’s price range in the past 12 months?
Eton Pharmaceuticals lowest stock price was $14.27 and its highest was $66.37 in the past 12 months.
What is Eton Pharmaceuticals’s market cap?
Eton Pharmaceuticals’s market cap is $1.45B.
When is Eton Pharmaceuticals’s upcoming earnings report date?
Eton Pharmaceuticals’s next earnings report is estimated for Nov 05, 2026 (not yet confirmed), which is in 1 day.
How were Eton Pharmaceuticals’s earnings last quarter?
Eton Pharmaceuticals released its earnings results on Aug 13, 2026. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.16.
Is Eton Pharmaceuticals overvalued?
According to Wall Street analysts Eton Pharmaceuticals’s price is currently Undervalued.
Does Eton Pharmaceuticals pay dividends?
Eton Pharmaceuticals does not currently pay dividends.
What is Eton Pharmaceuticals’s EPS estimate?
Eton Pharmaceuticals’s EPS estimate is 0.31.
How many shares outstanding does Eton Pharmaceuticals have?
Eton Pharmaceuticals has 28,583,136 shares outstanding.
What happened to Eton Pharmaceuticals’s price movement after its last earnings report?
Eton Pharmaceuticals reported an EPS of $0.35 in its last earnings report, beating expectations of $0.19. Following the earnings report the stock price went up 44.265%.
Which hedge fund is a major shareholder of Eton Pharmaceuticals?
Hedge funds hold Eton Pharmaceuticals shares: the largest hedge-fund position in Eton Pharmaceuticals is 71,884,858 shares, and hedge funds increased their holdings by 318.7K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology